Autopsy report · NCT03623568

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

“did not move forward with IRB approval, competing study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Raymond T. Chung, MD

Sponsor type

University, hospital or other

Conditions

Kidney Failure; Kidney Diseases; Hepatitis C

Interventions

glecaprevir/pibrentasvir tablets

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients
  “Study did not receive IRB approval, so did not start” (86% match in meaning)
• Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia
  “Study halted prematurely; IRB approval not obtained” (85% match in meaning)
• Antibiotics and Tissue Expanders in Breast Reconstruction
  “The study was withdrawn prior to IRB approval.” (82% match in meaning)
• Adherence to Otezla
  “Terminated IRB approval 6/26/2024, study was never initiated or activated” (81% match in meaning)
• Study Comparing Intubation Via Video Laryngeal Mask Airways (VLMAs) Versus Video Laryngoscopy
  “Study never approved by the IRB. Was not initiated” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.